STA 9090: all 37 studies that test it

Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.

• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingNCT01042379Phase 2
• European Trial on Enhanced DNA Repair Inhibition in Ovarian CancerCompletedNCT03783949Phase 2Results posted
• A Phase I/II Study of Ganetespib in Combination With DoxorubicinTerminatedNCT02261805Phase 1/2Results posted
• Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and SarcomasTerminatedNCT02192541Phase 1Results posted
• GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian CancerTerminatedNCT02012192Phase 1/2Results posted
• SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)CompletedNCT02008877Phase 1/2Results posted
• Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedNCT01962948Phase 1/2Results posted
• A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLCTerminatedNCT01798485Phase 3Results posted
• Fulvestrant With or Without Ganetespib in HR+ Breast CancerCompletedNCT01560416Phase 2Results posted
• STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV MelanomaTerminatedNCT01551693Phase 2Results posted
• Open-label Study of STA-9090 for Patients With Metastatic Breast CancerCompletedNCT01273896Phase 2Results posted
• Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based ChemotherapyCompletedNCT01270880Phase 2Results posted
• PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas CancerTerminatedNCT01227018Phase 2Results posted
• STA-9090(Ganetespib) in Metastatic Ocular MelanomaCompletedNCT01200238Phase 2Results posted
• Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung CancerCompletedNCT01173523Phase 2Results posted
• Clinical and Translational Study of STA-9090CompletedNCT01111838Phase 2Results posted
• A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)CompletedNCT01039519Phase 2Results posted
• A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast CancerWithdrawnNCT02637375Not applicable
• Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal CancerCompletedNCT02389751Phase 1
• Ganetespib Window of Opportunity Study in Head and Neck CancersTerminatedNCT02334319Phase 1
• Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast CancerCompletedNCT02060253Phase 1
• An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast CancerCompletedNCT01677455Phase 2
• STA-9090 in Patients With Advanced Hepatocellular CancerCompletedNCT01665937Phase 1
• Ganetespib With Platinum, in Patients With Malignant Pleural MesotheliomaCompletedNCT01590160Phase 1/2
• Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung CancersCompletedNCT01579994Phase 1
• A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)CompletedNCT01562015Phase 2
• Phase I Trial of Ganetespib, Capecitabine, and Radiation in Rectal CancerCompletedNCT01554969Phase 1
• A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple MyelomaCompletedNCT01485835Phase 1
• STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway SignalingWithdrawnNCT01368003Phase 2
• A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome.CompletedNCT01236144Phase 1/2
• A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid TumorsCompletedNCT01183364Phase 1
• STA-9090 in Previously Treated Patients With Advanced Esophagogastric CancerCompletedNCT01167114Phase 2
• A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)CompletedNCT01031225Phase 2
• A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous LeukemiaCompletedNCT00964873Phase 1
• STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative DisordersCompletedNCT00858572Phase 1
• Study of STA-9090, Administered Twice-Weekly in Patients With Solid TumorsStatus unknownNCT00688116Phase 1
• Study of STA-9090, Administered Once-Weekly in Patients With Solid TumorsCompletedNCT00687934Phase 1

← STA 9090 overview